Literature DB >> 15955898

Objective response rate as a surrogate end point: a commentary.

Thomas R Fleming.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15955898     DOI： 10.1200/JCO.2005.92.008

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib.

Authors:  Gary M Clark
Journal:  Mol Oncol       Date:  2007-12-08       Impact factor: 6.603

Review 2.  Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.

Authors:  Marcus Hezel; Kathrin von Usslar; Thiemo Kurzweg; Balazs B Lörincz; Rainald Knecht
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-09       Impact factor: 2.503

Review 3.  Is Participation in Cancer Phase I Trials Really Therapeutic?

Authors:  Jonathan Kimmelman
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

4.  Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Melinda Hollingshead; Glenn Merlino
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

5.  Model-based simulation to support the extended dosing regimens of atezolizumab.

Authors:  Chen-Hsi Chou; Li-Feng Hsu
Journal:  Eur J Clin Pharmacol       Date:  2020-08-17       Impact factor: 2.953

6.  Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Authors:  Beth Sherrill; James A Kaye; Rickard Sandin; Joseph C Cappelleri; Connie Chen
Journal:  Onco Targets Ther       Date:  2012-10-23       Impact factor: 4.147

7.  Assessing the outcomes of HIV-infected persons receiving treatment for Kaposi sarcoma in Conakry-Guinea.

Authors:  Cavin E Bekolo; Mohamed M Soumah; Ousseni W Tiemtore; Abdourahimi Diallo; Joseph-Desire Yuma; Letizia Di Stefano; Carol Metcalf; Mohamed Cisse
Journal:  BMC Cancer       Date:  2017-12-02       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.